Zymeworks (ZYME) shares slumped 46% pre-bell Tuesday, adding to Monday's losses.
Arvinas (ARVN) shares retreated 41% after the company and Pfizer (PFE) said their phase 3 trial of vepdegestrant for the treatment of breast cancer failed to reach statistical significance in improvement in progression free survival in the intent-to-treat population.
Evolus (EOLS) shares fell 36% after Monday's 6.6% loss.
Stoke Therapeutics (STOK) shares decreased 36% following a muted session.
Medallion Financial (MFIN) shares were down 32% after a 2.4% gain in the previous session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。